Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine after preoperative radiotherapy and TME for rectal cancer
ISRCTN36266738Phase 3Completed
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Oct 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in rectal adenocarcinoma and rectal cancer comparing Capecitabine with Observation (2 arms). Primary endpoint: Overall survival. Started Oct 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on ISRCTN36266738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36266738.